-
14
Jan
21
-
KemPharm’s KP415 and Serdexmethylphenidate (SDX) Prodrug to be Featured in Multiple Sessions at the 2021 APSARD Virtual Conference
-
News & Publications
KemPharm® is a clinical stage, specialty pharmaceutical company engaged in the development and discovery of proprietary prodrugs that are designed to be improved versions of widely prescribed and FDA approved products.
-
13
Jan
21
-
KemPharm Participating in BIO @ JPM and Fierce JPM Week 2021 Virtual Events During “J.P. Morgan Week 2021”
-
-
08
Jan
21
-
KemPharm Announces Pricing of $50 Million Public Offering of Common Stock and Warrants and Uplisting to The Nasdaq Capital Market
-
-
23
Dec
20
-
KemPharm Announces 1-for-16 Reverse Stock Split
-
-
22
Dec
20
-
KemPharm Files IND for KP879 for the Treatment of Stimulant Use Disorder
-
-
02
Dec
20
-
KemPharm Participates in KP415 Late-Cycle Communication Meeting with FDA
-
-
30
Nov
20
-
REMINDER: KemPharm and Corium to Co-Host “KP415 Market Opportunity and Commercialization Strategy” Investor Event
-
-
23
Nov
20
-
KemPharm Provides Update on Development Pipeline
-
-
18
Nov
20
-
KemPharm and Corium to Co-Host “KP415 Market Opportunity and Commercialization Strategy” Investor Event
-
-
29
Oct
20
-
KemPharm Reports Third Quarter 2020 Financial Results
-
-
26
Oct
20
-
KemPharm Postpones Special Meeting of Stockholders, Announces Date for Q3 2020 Results Call
-
-
22
Oct
20
-
KemPharm’s KP415 and Serdexmethylphenidate (SDX) Prodrug to be Featured in Multiple Sessions at the AACAP 2020 Virtual Meeting
-